The goal of this clinical research study is to learn if blinatumomab can help to control
Richter Transformation (RT, a type of blood cancer). The safety of this drug will also be
studied.
This is an investigational study. Blinatumomab is FDA approved and commercially available for
the treatment of acute lymphoblastic leukemia (ALL). It is investigational to use
blinatumomab to treat patients with RT. The study doctor can explain how the study drug is
designed to work.
Up to 21 participants will be enrolled in this study. All will take part at MD Anderson.